Ironwood Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $298.3M | $274.0M | $149.6M | $76.4M | $22.9M | $150.2M | $65.9M | $43.9M |
| Cost of Revenue | $19.1M | $1.9M | $12.0K | $5.3M | $7.2M | $965.0K | — | — |
| Gross Profit | $279.2M | $272.1M | $149.5M | $71.1M | $15.7M | $149.3M | — | — |
| Gross Margin | 93.6% | 99.3% | 100.0% | 93.1% | 68.5% | 99.4% | — | — |
| Operating Expenses | ||||||||
| Research & Development | $88.1M | $139.5M | $108.7M | $101.9M | $102.4M | $113.5M | $86.1M | $77.5M |
| SG&A Expense | $231.2M | $173.3M | $125.2M | $118.3M | $123.2M | $92.5M | $45.9M | $27.2M |
| Operating Income | $-15.4M | $-51.9M | $-102.1M | $-169.4M | $-252.0M | $-72.8M | $-66.1M | $-60.8M |
| Operating Margin | -5.2% | -18.9% | -68.3% | -221.6% | -1,101.4% | -48.4% | -100.4% | -138.6% |
| Interest Expense | $36.4M | $39.2M | $31.1M | $21.2M | $21.0M | $59.0K | $63.0K | $196.0K |
| Pretax Income | — | — | — | — | $-272.8M | $-72.6M | $-64.8M | $-59.4M |
| Income Tax Expense | $0 | $0 | $0 | $0 | — | — | $3.0K | $-2.9M |
| Net Income | $-116.9M | $-81.7M | $-142.7M | $-189.6M | $-272.8M | $-72.6M | $-64.9M | $-51.9M |
| Net Margin | -39.2% | -29.8% | -95.4% | -248.1% | -1,192.3% | -48.3% | -98.5% | -118.2% |
| EPS (Basic) | $-0.78 | $-0.56 | $-1.00 | $-1.39 | $-2.35 | $-0.68 | $-0.65 | $-0.59 |
| EPS (Diluted) | $-0.78 | $-0.56 | $-1.00 | $-1.39 | $-2.35 | $-0.68 | $-0.65 | $-0.59 |
| Shares Outstanding (Basic) | — | — | — | — | — | — | 99.9M | 89.7M |
| Shares Outstanding (Diluted) | — | — | — | — | — | — | 99.9M | 89.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |